Compare Cipla with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALEMBIC PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALEMBIC PHARMA CIPLA/
ALEMBIC PHARMA
 
P/E (TTM) x 21.9 15.4 142.1% View Chart
P/BV x 2.4 3.8 62.7% View Chart
Dividend Yield % 0.7 1.0 67.4%  

Financials

 CIPLA   ALEMBIC PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
ALEMBIC PHARMA
Mar-19
CIPLA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs678664 102.1%   
Low Rs484412 117.3%   
Sales per share (Unadj.) Rs198.2208.7 95.0%  
Earnings per share (Unadj.) Rs18.531.0 59.8%  
Cash flow per share (Unadj.) Rs35.037.1 94.3%  
Dividends per share (Unadj.) Rs3.005.50 54.5%  
Dividend yield (eoy) %0.51.0 50.5%  
Book value per share (Unadj.) Rs186.3144.2 129.2%  
Shares outstanding (eoy) m805.70188.52 427.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.92.6 113.6%   
Avg P/E ratio x31.417.4 180.6%  
P/CF ratio (eoy) x16.614.5 114.5%  
Price / Book Value ratio x3.13.7 83.5%  
Dividend payout %16.217.7 91.3%   
Avg Mkt Cap Rs m468,031101,461 461.3%   
No. of employees `00022.6NA-   
Total wages/salary Rs m28,5657,467 382.6%   
Avg. sales/employee Rs Th7,053.1NM-  
Avg. wages/employee Rs Th1,261.5NM-  
Avg. net profit/employee Rs Th659.1NM-  
INCOME DATA
Net Sales Rs m159,71039,347 405.9%  
Other income Rs m4,76694 5,080.7%   
Total revenues Rs m164,47539,441 417.0%   
Gross profit Rs m30,9738,736 354.6%  
Depreciation Rs m13,2631,152 1,151.0%   
Interest Rs m1,684184 914.9%   
Profit before tax Rs m20,7917,493 277.5%   
Minority Interest Rs m-17211 -1,589.8%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6951,568 363.3%   
Profit after tax Rs m14,9245,844 255.4%  
Gross profit margin %19.422.2 87.3%  
Effective tax rate %27.420.9 130.9%   
Net profit margin %9.314.9 62.9%  
BALANCE SHEET DATA
Current assets Rs m124,26619,577 634.7%   
Current liabilities Rs m37,71514,896 253.2%   
Net working cap to sales %54.211.9 455.5%  
Current ratio x3.31.3 250.7%  
Inventory Days Days9190 101.0%  
Debtors Days Days9545 209.2%  
Net fixed assets Rs m105,19027,097 388.2%   
Share capital Rs m1,611377 427.4%   
"Free" reserves Rs m148,51126,811 553.9%   
Net worth Rs m150,12327,188 552.2%   
Long term debt Rs m38,3014,993 767.1%   
Total assets Rs m239,63347,778 501.6%  
Interest coverage x13.341.7 32.0%   
Debt to equity ratio x0.30.2 138.9%  
Sales to assets ratio x0.70.8 80.9%   
Return on assets %6.912.6 54.9%  
Return on equity %9.921.5 46.3%  
Return on capital %11.823.6 50.2%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41019,453 295.1%   
Fx outflow Rs m19,0416,065 314.0%   
Net fx Rs m38,36813,388 286.6%   
CASH FLOW
From Operations Rs m16,9118,120 208.3%  
From Investments Rs m-16,687-7,556 220.8%  
From Financial Activity Rs m-3,487590 -590.7%  
Net Cashflow Rs m-3,4511,153 -299.2%  

Share Holding

Indian Promoters % 16.0 74.1 21.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 2.9 420.7%  
FIIs % 23.7 9.1 260.4%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 13.9 188.5%  
Shareholders   161,166 49,328 326.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Developments in the Telecom Space, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets traded on a volatile note throughout the day and ended flat. The BSE Sensex closed higher by 42 points to end the day at 40,487.

Related Views on News

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)

Nov 27, 2019

The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 9, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS